Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2005 Dec;76(12):1670–1676. doi: 10.1136/jnnp.2004.045765

Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients

P Gallien 1, J Reymann 1, G Amarenco 1, B Nicolas 1, M de Seze 1, E Bellissant 1
PMCID: PMC1739451  PMID: 16291892

Abstract

Objective: The purpose of the study was to evaluate the efficacy and safety of botulinum A toxin in the treatment of detrusor sphincter dyssynergia in multiple sclerosis patients.

Methods: This was a multicentre, placebo controlled, randomised, double blind study. Patients with chronic urinary retention were included if they had post-voiding residual urine volume between 100 and 500 ml. They received a single transperineal injection of either botulinum A toxin (100 U Allergan) or placebo in the sphincter and also 5 mg slow release alfuzosin bid over 4 months. Main endpoint was post-voiding residual urine volume assessed 1 month after injection. Follow up duration was 4 months. Statistical analysis was performed using a sequential method, the triangular test.

Results: The study was stopped after the fourth analysis (86 patients had been included: placebo: 41, botulinum A toxin: 45). At inclusion, there was no significant difference between groups whichever variable was considered. Mean (standard deviation) post-voiding residual urine volume was 217 (96) and 220 (99) ml in placebo and botulinum A toxin groups, respectively. One month later, post-voiding residual urine volume was 206 (145) and 186 (158) ml (p = 0.45) in placebo and botulinum A toxin groups, respectively. However, compared to placebo, botulinum A toxin significantly increased voiding volume (+54%, p = 0.02) and reduced pre-micturition (–29%, p = 0.02) and maximal (–21%, p = 0.02) detrusor pressures. Other secondary urodynamic endpoints and tolerance were similar in the two groups.

Conclusions: In multiple sclerosis patients with detrusor sphincter dyssynergia, a single injection of botulinum A toxin (100 U Allergan) does not decrease post-voiding residual urine volume.

Full Text

The Full Text of this article is available as a PDF (88.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen J. T., Bradley W. E. The syndrome of detrusor-sphincter dyssynergia. J Urol. 1976 Oct;116(4):493–495. doi: 10.1016/s0022-5347(17)58875-8. [DOI] [PubMed] [Google Scholar]
  2. Barbalias G. A., Nikiforidis G., Liatsikos E. N. Vesicourethral dysfunction associated with multiple sclerosis: clinical and urodynamic perspectives. J Urol. 1998 Jul;160(1):106–111. [PubMed] [Google Scholar]
  3. Blaivas J. G., Barbalias G. A. Detrusor-external sphincter dyssynergia in men with multiple sclerosis: an ominous urologic condition. J Urol. 1984 Jan;131(1):91–94. doi: 10.1016/s0022-5347(17)50216-5. [DOI] [PubMed] [Google Scholar]
  4. Brading A. F. A myogenic basis for the overactive bladder. Urology. 1997 Dec;50(6A):57–73. doi: 10.1016/s0090-4295(97)00591-8. [DOI] [PubMed] [Google Scholar]
  5. Dykstra D. D., Sidi A. A., Scott A. B., Pagel J. M., Goldish G. D. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988 May;139(5):919–922. doi: 10.1016/s0022-5347(17)42717-0. [DOI] [PubMed] [Google Scholar]
  6. Dykstra D. D., Sidi A. A. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil. 1990 Jan;71(1):24–26. [PubMed] [Google Scholar]
  7. Gallien P., Robineau S., Nicolas B., Le Bot M. P., Brissot R., Verin M. Vesicourethral dysfunction and urodynamic findings in multiple sclerosis: a study of 149 cases. Arch Phys Med Rehabil. 1998 Mar;79(3):255–257. doi: 10.1016/s0003-9993(98)90003-x. [DOI] [PubMed] [Google Scholar]
  8. Gallien P., Robineau S., Verin M., Le Bot M. P., Nicolas B., Brissot R. Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch Phys Med Rehabil. 1998 Jun;79(6):715–717. doi: 10.1016/s0003-9993(98)90050-8. [DOI] [PubMed] [Google Scholar]
  9. Kim Y. H., Goodman C., Omessi E., Rivera V., Kattan M. W., Boone T. B. The correlation of urodynamic findings with cranial magnetic resonance imaging findings in multiple sclerosis. J Urol. 1998 Mar;159(3):972–976. [PubMed] [Google Scholar]
  10. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  11. Leippold Thomas, Reitz André, Schurch Brigitte. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol. 2003 Aug;44(2):165–174. doi: 10.1016/s0302-2838(03)00250-1. [DOI] [PubMed] [Google Scholar]
  12. Litwiller S. E., Frohman E. M., Zimmern P. E. Multiple sclerosis and the urologist. J Urol. 1999 Mar;161(3):743–757. [PubMed] [Google Scholar]
  13. Petit H., Wiart L., Gaujard E., Le Breton F., Ferrière J. M., Lagueny A., Joseph P. A., Barat M. Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord. 1998 Feb;36(2):91–94. doi: 10.1038/sj.sc.3100517. [DOI] [PubMed] [Google Scholar]
  14. Phelan M. W., Franks M., Somogyi G. T., Yokoyama T., Fraser M. O., Lavelle J. P., Yoshimura N., Chancellor M. B. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol. 2001 Apr;165(4):1107–1110. [PubMed] [Google Scholar]
  15. Poser C. M., Paty D. W., Scheinberg L., McDonald W. I., Davis F. A., Ebers G. C., Johnson K. P., Sibley W. A., Silberberg D. H., Tourtellotte W. W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
  16. Schurch B., Hauri D., Rodic B., Curt A., Meyer M., Rossier A. B. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol. 1996 Mar;155(3):1023–1029. doi: 10.1016/s0022-5347(01)66376-6. [DOI] [PubMed] [Google Scholar]
  17. Sébille V., Bellissant E. Comparison of the two-sided single triangular test to the double triangular test. Control Clin Trials. 2001 Oct;22(5):503–514. doi: 10.1016/s0197-2456(01)00154-4. [DOI] [PubMed] [Google Scholar]
  18. Sébille Véronique, Bellissant Eric. Sequential methods and group sequential designs for comparative clinical trials. Fundam Clin Pharmacol. 2003 Oct;17(5):505–516. doi: 10.1046/j.1472-8206.2003.00192.x. [DOI] [PubMed] [Google Scholar]
  19. Wanner M. B., Rageth C. J., Zäch G. A. Pregnancy and autonomic hyperreflexia in patients with spinal cord lesions. Paraplegia. 1987 Dec;25(6):482–490. doi: 10.1038/sc.1987.81. [DOI] [PubMed] [Google Scholar]
  20. de Groat W. C. A neurologic basis for the overactive bladder. Urology. 1997 Dec;50(6A):36–56. doi: 10.1016/s0090-4295(97)00587-6. [DOI] [PubMed] [Google Scholar]
  21. de Sèze Marianne, Petit Hervé, Gallien Philippe, de Sèze Mathieu-Panchoa, Joseph Pierre-Alain, Mazaux Jean-Michel, Barat Michel. Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol. 2002 Jul;42(1):56–62. doi: 10.1016/s0302-2838(02)00209-9. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES